Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Hypertransaminasaemia? 149 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 149 reports of Hypertransaminasaemia have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.2% of all adverse event reports for DOXORUBICIN.

149
Reports of Hypertransaminasaemia with DOXORUBICIN
0.2%
of all DOXORUBICIN reports
5
Deaths
52
Hospitalizations

How Dangerous Is Hypertransaminasaemia From DOXORUBICIN?

Of the 149 reports, 5 (3.4%) resulted in death, 52 (34.9%) required hospitalization, and 16 (10.7%) were considered life-threatening.

Is Hypertransaminasaemia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 149 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Hypertransaminasaemia?

METHOTREXATE (436) ACETAMINOPHEN (326) PACLITAXEL (318) CARBOPLATIN (304) PEMBROLIZUMAB (231) ATORVASTATIN (207) CYCLOPHOSPHAMIDE (202) PREDNISONE (198) GEMCITABINE (196) DEXAMETHASONE (169)

Which DOXORUBICIN Alternatives Have Lower Hypertransaminasaemia Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Hypertransaminasaemia Reports All Drugs Causing Hypertransaminasaemia DOXORUBICIN Demographics